NCT01620359View on ClinicalTrials.gov

Study of ExAblate Focused Ultrasound Ablation of Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Breast Cancer
Interventions
DEVICE

ExAblate MRgFUS

100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor

Trial Locations (1)

46236

Marienhospital, Bottrop

Sponsors

Lead Sponsor

InSightec
All Listed Sponsors
lead

InSightec

INDUSTRY

NCT01620359 - Study of ExAblate Focused Ultrasound Ablation of Breast Cancer | Biotech Hunter | Biotech Hunter